Objective: To study the diagnostic, etiological, therapeutic and evolutionary aspects of patients received at the Sylvanus Olympio Hospital in Lomé for venous priapism. Patients and Methods: A cross sectional study, over 5 years (2012-2016), of 27 cases of low flow priapism treated at the Chu Sylvanus Olympio in Lomé. Results: The mean age of the patients was 28.14 years ± 8.6. The average time of consultation was 106 hours (04 days 10 hours) ± 208.02. In our study, 4 (14.81%) patients consulted before the 6th hour and 20 (74%) patients consulted after the 24th hour. The blood count required in all patients revealed a case of chronic myeloid leukemia. Hemoglobin electrophoresis resulted in 23 (85.1%) cases of sickle cell disease. The management was medico-surgical. After an average follow-up of 11 months, erectile function was evaluated in 18 patients, and erectile dysfunction was noted in 10 (55.5%) patients.
References
[1]
Dekou, A., Ouegnin, G.A., Konan, P.G., Kouame, B. and Manzan, K. (2006) The Etiologies and Risk Factors of Priapism from a Series Collected in the Urology Department of the Cocody Teaching Hospital in Abidjan. Revue Internationale des Sciences Medicales d’Abidjan, 8, 27-30.
[2]
Fall, P.A., Diao, B., Ndoye, A.K., Ndiaye Diop, E., Sylla, C., Gueye, S.M. and Diagne, B.A. (2005) Priapism: Clinical and Etiological Specificities. Department of Urology-Andrology, A. Dantec and Hoggy Hospital, Dakar, Senegal. African Journal of Urology, 11, 186-190.
[3]
Gbadoe, A.D., Dogba, A., Segbena, A.Y., Nyadanu, D.Y., et al. (2001) Priapism in Sickle Cell Anemia in Togo, Prevalence and Knowledge of This Complication. Hemoglobin, 25, 355-361. https://doi.org/10.1081/HEM-100107871
[4]
Slimen, M.H., Fakhfakh, H., Gassara, M., Kechaou, S., Bahloul, A. and Mhiri, M.N. (2008) Venous Priapism: Treatment and Functional Prognosis about 26 Cases. Urology Department, Habib Bourguiba University Hospital, Sfax, Tunisia. Andrology, 18, 264-273.
[5]
Kamel, K., Mohamed, M., Abderrazek, B., Mohamed, C., Amine, D., Riadh, B.S., et al. (2016) Management of Low-Dose Priapism Seen Late: About 28 Cases. AJU, 22, 297-304.
[6]
Mantadakis, E., Cavender, J.D., Rogers, Z.R., Ewalt, D.H. and Buchanan, G.R. (1999) Prevalence of Priapism in Children and Adolescents with Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 21, 518-522. https://doi.org/10.1097/00043426-199911000-00013
[7]
Okoko, A.R., Odzebe, A.S.W., Middle, E., Ekouya Bowassa, G., Oko, A.P.G, Mbika-Cardorelle, A., et al. (2014) Priapism in Children and Homozygous Sickle Cell Patients in Brazzaville. Progrès en Urologie, 24, 57-61. https://doi.org/10.1016/j.purol.2013.04.021
[8]
Majeed, S., Schor, J.A., Jacobson, S., Jagoda, A. and Mahadeo, R. (2000) Refractory Priapism of Unknown Etiology in a Pediatric Patient. Pediatric Emergency Care, 16, 347-351. https://doi.org/10.1097/00006565-200010000-00012
Fall, B., Fall, P.A., Diao, B., Sow, Y., Dieng, E., Sarr, A., et al. (2010) Acute Priapism in Senegalese Sickle Cell Disease: Clinical, Therapeutic and Evaluation Aspects of Erectile Function. Andrology Urology Department, University Hospital Aristide Le Dantec Med. Medecine Tropicale, 70, 475-478.
[11]
Marrag, I., Ben Soussia, R., Hajji, K., Zarrouk, L., Binous, Y. and Nasr, M. (2016) Chlorpromazine Induced Priapism: Two Cases Reports. African Journal of Urology, 22, 131-135. https://doi.org/10.1016/j.afju.2015.05.006
[12]
Brichart, N., Delavierre, D., Peneau, M., Ibrahim, H. and Mallek, A. (2008) Priapism Associated with Antipsychotic Medications: A Series of Four Patients. Progrès en Urologie, 18, 669-673. https://doi.org/10.1016/j.purol.2008.04.010
[13]
Droupy, S. and Giuliano, F. (2013) Priapisms. Progrès en Urologie, 23, 638-646. https://doi.org/10.1016/j.purol.2013.01.026
[14]
Dahm, P., Rao, D.S. and Donatucci, C.F. (2002) Antiandrogens in the Treatment of Priapism. Urology, 59, 138. https://doi.org/10.1016/S0090-4295(01)01492-3
[15]
Kousournas, G., Muneer, A., Ralph, D. and Zacharakis, E. (2017) Contemporary Best Practice in the Evaluation and Management of Stuttering Priapism. Therapeutic Advances in Urology, 9, 227-238. https://doi.org/10.1177/1756287217717913
[16]
Champion, H.C., Bivalacqua, T.J., Takimoto, E., Kass, D.A. and Burnett, A.L. (2005) Phosphodiesterase-5A Dysregulation in Penil Erectile Tissue Is a Mechanism of Priapism. Proceedings of the National Academy of Sciences of the United States of America, 102, 1661-1666. https://doi.org/10.1073/pnas.0407183102
Bivalacqua, T.J., Champion, H.C., Mason, W. and Burnett, A.L. (2006) Long-Term Phosphodiesterase Type 5 Inhibitor Therapy Reduces Priapic Activity in Transgenic Sickle Cell Mice. The Journal of Urology, 175, 387. https://doi.org/10.1016/S0022-5347(18)33427-X
[19]
Burnett, A.L., Bivalacqua, T.J., Champion, H.C. and Musicki, B. (2006) Long-Term Oral Phosphodiesterase-5 Inhibitor Therapy Recurrent Alleviates Priapism. 100th Meeting American Urological Association, Atlanta, 21-25 May 2006. Urology, 67, 1043-1048.
[20]
Chinagwundoh, F.I., Smith, S. and Anie, K.A. (2017) Treatments for Priapism in Boys and Men with Sickle Disease. Cochrane Database of Systematic Reviews, 9, CD004198.
[21]
Khoriaty, A.V. and Schick, E. (1980) The Surgery of Priapism. The Journal of Urology, 86, 283-291.
[22]
Bondil, P. (1986) Iatrogenic Priapism by Intracavernous Injection of Vasoactive Drugs in the Treatment of Impotence. Presse Medicale, 15, 655.
[23]
Gerstenbluth, R.E., Kick, P.S., Srodes, A.D. and Seftel, A.D. (2003) Priapism Secondary to Hypertriglyceridemia. The Journal of Urology, 169, 1088. https://doi.org/10.1097/01.ju.0000052645.28725.af
